Navigation Links
Lexicon Initiates Phase 2 Clinical Trial of LX1032 in Patients With Carcinoid Syndrome
Date:7/7/2009

no longer respond to the standard of care under Fast Track designation from the U.S. Food and Drug Administration.

About Carcinoid Syndrome

Carcinoid syndrome is a chronic condition caused by metastatic neuroendocrine tumors that usually originate from the gastrointestinal tract. These tumors secrete large amounts of serotonin, which can cause a variety of symptoms including severe diarrhea and abdominal discomfort. Patients with carcinoid syndrome currently have limited therapeutic options, and the standard of care includes chronic therapy with somatostatin analogues, which are delivered by injection. With current therapy, the gastrointestinal symptoms return over time in the vast majority of patients, hence the need for new agents.

About Lexicon

Lexicon is a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease. Lexicon currently has five drug candidates in development for autoimmune disease, carcinoid syndrome, diabetes, glaucoma and irritable bowel syndrome, all of which were discovered by the company's research team. The company has used its proprietary gene knockout technology to identify more than 100 promising drug targets. Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs. For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement

This press release contains "forward-looking statements," including statements relating to Lexicon's clinical development of LX1032 and the potential therapeutic and commercial potential of LX1032. This press release also contains forward-looking statements relating to Lexicon's growth and future operating results, discovery and development of
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Lexicon Names Ajay Bansal Executive Vice President and Chief Financial Officer
2. Lexicon to Present Clinical Data for LX1031 and LX1032 at Digestive Disease Week
3. Lexicon to Provide Clinical Pipeline Update and Report First Quarter 2009 Financial Results on April 28, 2009
4. Lexicon Pharmaceuticals 2008 Annual Report to Stockholders Available Online
5. Nuevolution Announces Drug Discovery Alliance With Lexicon Pharmaceuticals
6. Lexicon to Report Fourth Quarter and Full Year 2007 Financial Results on March 6, 2008
7. Lexicon Files Investigational New Drug Application for LX1032 as a Potential Treatment for Carcinoid Syndrome
8. Lexicon Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
9. Lexicon Pharmaceuticals to Present at the Piper Jaffray 19th Annual Health Care Conference
10. Lexicon Pharmaceuticals Reports 2007 Third Quarter Financial Results
11. Lexicon to Report Third Quarter 2007 Financial Results on October 30, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... A major challenge before new biotechnology start-up ... of Boston-Cambridge, is gaining visibility that can lead to ... Director of Boston’s Adult Stem Cell Technology Center, LLC ... of his company an important priority since he started ... a social media marketing campaign launched earlier ...
(Date:8/28/2014)... “This kit has an improved extraction efficiency and provides ... ppb,” said Mark Tess, PhD, Mycotoxin Product Manager for Charm ... and USDA-GIPSA inspection agencies that have a need to detect ... in a matter of minutes with nothing but our equipment ... and grain before accepting it, but they no longer have ...
(Date:8/28/2014)... , Aug. 28, 2014  Next month, executives from clinical ... key industry events beginning with Patient-Centered Clinical Trials 2014 ... Boston , September 4-5. Patient recruitment experts ... Aaron Fleishman will share insights on the benefits ... variety of tactics – from media to mobile apps – ...
(Date:8/28/2014)... USA (PRWEB) August 27, 2014 Scientists, ... month for SPIE Laser Damage 2014 symposium. ... materials for high-power lasers will run 14-17 September. The ... for optics and photonics . , The premier conference ... understanding laser damage to optical materials will engage researchers ...
Breaking Biology Technology:The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 2The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 3The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 4BBK Worldwide Leads Sessions at Key September Events 2Laser Damage to Draw Researchers, Engineers, Scientists to 46th Annual Conference 2Laser Damage to Draw Researchers, Engineers, Scientists to 46th Annual Conference 3
... Mass., Jan. 6, 2011 GENFIT (Alternext: ALGFT; ISIN: ... discovery and development, focusing on the early diagnosis and ... its presence at two U.S. events: the 28th J.P. ... and the Biotech Showcase (from January 10th to 12th, ...
... 2011 Verenium Corporation (Nasdaq: VRNM ), ... industrial enzyme solutions, today announced that the ... has been dismissed.  Verenium,s motion for summary judgment to ... District Court for the Southern District of New York. ...
... CARLSBAD, Calif., Jan. 6, 2011 Isis Pharmaceuticals, Inc. ... has added two new drugs to its development pipeline, ... to treat obesity by increasing metabolism, particularly by increasing ... of fibroblast growth factor receptor 4 (FGFR4) in the ...
Cached Biology Technology:GENFIT: Strong U.S. Exposure for Its Biomarker Activity 2GENFIT: Strong U.S. Exposure for Its Biomarker Activity 3Verenium Announces Favorable Outcome of Capital Ventures International Lawsuit 2Verenium Announces Favorable Outcome of Capital Ventures International Lawsuit 3Isis Pharmaceuticals Adds Two New Drugs to Development Pipeline 2Isis Pharmaceuticals Adds Two New Drugs to Development Pipeline 3Isis Pharmaceuticals Adds Two New Drugs to Development Pipeline 4
(Date:8/28/2014)... a significant health risk to people with asthma according to ... and Clinical Immunology . , By critically reviewing the findings ... found that the presence of several types of mould can ... increasing the likelihood of developing the condition. , The research ... Exeter Medical School and is the first time all of ...
(Date:8/28/2014)... Munich have assigned a number of 435-million-year-old fossils ... animals lived in shallow marine habitats and were ... Jurassic strata. , Before they sank to ... were fossilized some 435 million years ago, these ... seas although they were not exactly inconspicuous, ...
(Date:8/27/2014)... North America,s megafauna mastodons, short-faced bears, giant ground ... disappeared close to 13,000 years ago at the end ... extinction has long been debated by scientists who, until ... group of scientists, including UC Santa Barbara,s James Kennett, ... that a comet collision with Earth played a major ...
Breaking Biology News(10 mins):Indoor mold poses health risk to asthma sufferers 2Paleontology: Oldest representative of a weird arthropod group 2Nanodiamonds are forever 2Nanodiamonds are forever 3
... away at the problem of antibiotic resistance now have ... target in bacteria evolves to become resistant to some ... new experimental antibiotics that are being engineered to circumvent ... Led by Thomas A. Steitz, a Howard Hughes Medical ...
... as disturbance makes a landscape susceptible to invasion by ... globe could be contributing to the accelerating spread of ... the June 2005 issue of BioScience. John A. Havel ... and M. Jake Vander Zanden of the University of ...
... ever covered a flashlight with your hand and seen the ... light in the therapeutic window ?that magic wavelength that is ... they can use light at that wavelength to signal manmade ... , Such possibilities will be discussed in a poster and ...
Cached Biology News:Researchers make gains in understanding antibiotic resistance 2Researchers make gains in understanding antibiotic resistance 3Reservoirs may accelerate the spread of invasive aquatic species, researchers say 2Medical molecules designed to respond to visible light that can penetrate tissue 2
Mouse monoclonal [2A4] to Cytokeratin 8 + 18 + 19 ( Abpromise for all tested applications). Antigen: Cytokeratins isolated from cultured pig kidney epithelial cells. Entrez GeneID: 3856 S...
Tube-O-DIALYZER Floats, small....
Nestin, Human...
Rabbit polyclonal to Survivin DEx3 ( Abpromise for all tested applications). entrezGeneID: 332 SwissProtID: O15392...
Biology Products: